Lanean...
CD4+ count‐dependent concentration–effect relationship of rituximab in rheumatoid arthritis
AIMS: Rituximab is approved in rheumatoid arthritis (RA). A substantial decrease in CD4+ count was observed in responders after a single cycle of treatment. This study aimed to describe and quantifying the influence of CD4+ count depletion on the concentration–response relationship of rituximab in R...
Gorde:
| Argitaratua izan da: | Br J Clin Pharmacol |
|---|---|
| Egile Nagusiak: | , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
John Wiley and Sons Inc.
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6955400/ https://ncbi.nlm.nih.gov/pubmed/31454097 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.14102 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|